(TLSI) TriSalus Life Sciences, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TLSI) TriSalus Life Sciences, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This TriSalus Life Sciences, Inc. 4P's Marketing Mix Analysis explains the company’s product, pricing, distribution, and promotion strategies and shows how they support positioning and sales; the page already contains a real preview/sample of the analysis so you can review style and content, and purchasing the full version delivers the complete ready-to-use report.
Product
TriNav Infusion System
TriNav Infusion System is TriSalus Life Sciences’ flagship hepatic arterial infusion platform, built to deliver therapy straight to liver tumors in interventional oncology. Liver cancer still causes about 760,000 deaths a year worldwide, so targeted delivery matters. The system supports localized treatment, aiming to raise drug exposure at the tumor while limiting whole-body impact.
Pancreatic Retrograde Venous Infusion System
TriSalus Life Sciences, Inc.’s Pancreatic Retrograde Venous Infusion System targets pancreatic tumors with a retrograde venous delivery route designed to improve drug access in a cancer that caused about 67,440 new U.S. cases and 51,980 deaths in 2025.
It broadens TriSalus beyond liver-focused interventions, giving the company a second tumor-access platform.
In the product mix, this is a high-differentiation, procedure-linked offering aimed at a hard-to-treat market with very poor outcomes.
SD-101 investigational therapy
SD-101 is TriSalus Life Sciences, Inc.’s investigational immunotherapeutic candidate, delivered with pressure-enabled drug delivery to push therapy deeper into tumors. It targets a large need: solid tumors account for about 90% of adult cancers. The program is being studied across multiple solid-tumor indications, which can broaden its commercial reach if clinical data hold.
Pressure-enabled delivery platform
TriSalus Life Sciences, Inc.’s pressure-enabled delivery platform is the core of its product strategy. It is designed to raise local drug delivery in hard-to-reach tumors by using controlled pressure to move therapy deeper into tissue. This is the company’s key clinical and commercial differentiator.
- Targets difficult tumor sites
- Improves local drug concentration
- Supports TriSalus’ core positioning
Liver and pancreatic oncology focus
TriSalus Life Sciences, Inc. focuses its liver and pancreatic oncology portfolio on high-unmet-need tumors: hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic ductal adenocarcinoma. Globally, liver cancer causes about 865,000 new cases a year, and pancreatic cancer causes about 511,000, which shows why these settings stay priority areas. The company also targets metastatic liver disease, expanding use across hard-to-treat solid tumors.
- High unmet need cancer focus
- HCC, iCCA, and PDAC
- Metastatic liver disease included
- Large global patient burden
TriSalus Targets Hard-to-Treat Cancers with Precision Delivery
TriSalus Life Sciences, Inc. sells a niche oncology product set built around pressure-enabled delivery: TriNav for liver tumors, a pancreatic venous infusion system, and SD-101 as the lead immunotherapy asset. The focus is high-unmet-need cancers, including HCC, iCCA, and PDAC, where targeted local delivery can matter more than broad systemic dosing.
| Product | Use |
|---|---|
| TriNav | Liver tumors |
| Pancreatic system | PDAC |
| SD-101 | Solid tumors |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P analysis of TriSalus Life Sciences, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Condenses TriSalus Life Sciences’ 4Ps into a quick, actionable snapshot that helps teams spot gaps and align faster.
Reference Sources
Provides a concise bibliography linking each key TriSalus Life Sciences claim to primary industry reports, government data, and benchmarked datasets for fast due diligence.
Place
Westminster, Colorado headquarters
TriSalus Life Sciences is headquartered in Westminster, Colorado, its central corporate and operating base. The site anchors executive, development, and commercial coordination for the Company. As of its 2025 filings, this hub supports the scale-up of its oncology-focused platform and U.S. market execution.
Specialty hospital channels
TriSalus Life Sciences, Inc. uses specialty hospital channels, so its products reach patients through hospitals and specialty procedure centers, not consumer retail. This fits interventional oncology, where care is delivered in clinical settings and access is tied to physician-led procedures. U.S. delivery is concentrated: over 6,000 hospitals and about 6,500 ambulatory surgery centers shape these buying points.
Interventional oncology sites
Interventional oncology sites are the core Place channel for TriSalus Life Sciences, Inc. because they serve catheter-based cancer procedures inside interventional radiology and oncology programs. Access depends on physician adoption and hospital procurement, so site selection often hinges on procedure volume, device training, and formulary approval. In 2025, the U.S. still had about 6,000 hospitals and many more outpatient centers, but only a small share run these specialty programs.
U.S. clinical and commercial footprint
TriSalus Life Sciences, Inc. is still U.S.-centered: market access depends on provider networks, site-level adoption, and oncology physicians willing to place the device in routine care. Trial activity and direct clinician relationships help widen reach, but commercial scale stays tied to U.S. clinical uptake.
- U.S. market is the main access base.
- Provider networks drive placement.
- Physician adoption supports commercial reach.
- Clinical trials help expand awareness.
Direct clinician engagement
TriSalus Life Sciences, Inc. uses direct clinician engagement to place its therapy and device model where procedures happen: with physicians, nurses, and care teams. For complex adoption, that matters because buying decisions in interventional care are made at the point of use, not in a retail channel. It also helps the Company train users and support workflow fit in real time.
- Reaches procedure teams directly
- Supports complex adoption
- Keeps product near use site
TriSalus Pushes Oncology Products Through U.S. Hospitals and Specialty Centers
TriSalus Life Sciences, Inc. places its oncology products through U.S. hospitals and specialty procedure centers, where interventional radiology teams make the buy and use decisions. Its Westminster, Colorado base supports sales, training, and clinical coordination. With about 6,000 U.S. hospitals and 6,500 ambulatory surgery centers, reach depends on physician adoption and site-level approval. Direct clinician engagement keeps the product close to the procedure site.
| Place factor | Data |
|---|---|
| Headquarters | Westminster, Colorado |
| U.S. hospitals | About 6,000 |
| ASCs | About 6,500 |
| Channel | Hospital and specialty care |
Preview Before You Purchase
TriSalus Life Sciences, Inc. Reference Sources
The preview shown here is the actual, full 4P's Marketing Mix analysis for TriSalus Life Sciences, Inc. you'll receive instantly after purchase—complete, editable, and ready to use without any hidden extras.
Promotion
Clinical trial readouts
TriSalus Life Sciences, Inc. uses clinical trial readouts to drive awareness of its pipeline, since study results are the core proof point for physicians and investors. That matters most for investigational SD-101, where adoption depends on clear data from ongoing clinical studies. In oncology, even a single clean readout can shift view of safety, response, and next-step trial design.
Medical conference presence
TriSalus Life Sciences, Inc. can use medical conferences and scientific meetings to reach interventional oncologists, hepatologists, and surgeons where treatment decisions are made. Major events like the ASCO Annual Meeting draw more than 40,000 oncology professionals, giving the company wide specialist reach and direct peer review. That visibility helps build clinical credibility and supports adoption in a trust-based market.
Peer-reviewed clinical evidence
Peer-reviewed clinical evidence is a core promotion tool for TriSalus Life Sciences, Inc., because published data helps physicians assess safety and efficacy before adoption. In medtech, studies in indexed journals also support market validation and can shape reimbursement talks. For TriSalus, strong clinical proof is key to making its product claims credible and relevant to practice.
Physician education
Physician education is the core of TriSalus Life Sciences, Inc. promotion because its procedure-based products need hands-on training, clear device-use demos, and delivery guidance. Adoption rises when clinicians are familiar with the technology, and in medtech, trained users tend to move faster from trial to routine use.
- Train clinicians on use and delivery.
- Support adoption through familiarity.
- Use education to drive repeat use.
Investor and corporate communications
As a Nasdaq-listed public life sciences company, TriSalus Life Sciences, Inc. uses corporate updates, earnings releases, and SEC filings to show pipeline progress and business milestones. This investor and corporate communications work helps keep the market informed and can support capital access, especially after its $15.1 million Q1 2025 revenue and continued development-stage spending. Clear, frequent updates matter because they link clinical progress to financing credibility.
- Reinforces pipeline and milestone progress
- Supports market visibility and capital access
TriSalus Banks on Clinical Proof to Win Oncology Adoption
TriSalus Life Sciences, Inc. promotes through clinical data, because oncology adoption depends on proof, not hype. Q1 2025 revenue was $15.1 million, so clear investor and physician messaging also matters for capital access. Conference visibility, peer-reviewed papers, and physician training are the main tools.
| Promotion channel | Why it matters | Data point |
|---|---|---|
| Clinical trials | Builds trust | Q1 2025 revenue: $15.1M |
| Conferences | Reaches specialists | ASCO draws 40,000+ attendees |
Price
Public list price not disclosed
TriSalus Life Sciences does not publish a standard list price, so the public price is effectively $0 disclosed. In hospital devices and therapies, pricing is usually negotiated by provider, IDN, and payer, with contract terms kept off market-facing pages. Exact rates are shared through sales and reimbursement channels, not consumer-style catalogs.
Hospital procurement pricing
TriNav and related systems are likely bought through hospital procurement, not direct retail, so price is judged against clinical utility and reimbursement. In 2025-26, this matters because hospitals face tight budget cycles and value-based buying, where a device must clear committee review, payer coverage, and ROI checks before adoption.
Procedure-based reimbursement
Adoption in interventional oncology often hinges on procedure-based reimbursement, because hospitals need the case to clear payer and site-of-care economics. CMS’s 2025 hospital outpatient update was 2.9%, so pricing must fit tight margins and support utilization. TriSalus Life Sciences, Inc. can win coverage faster when clinical data shows fewer complications and stronger downstream value.
Investigational SD-101 not commercially priced
SD-101 is still investigational, so TriSalus Life Sciences, Inc. does not publish a standard retail price. Any patient cost is usually limited to clinical-trial expenses, while the product’s value is tied to development progress rather than sales. In Q2 2026, TriSalus reported continued R&D spending, which fits a trial-stage asset with no commercial pricing.
- No commercial list price
- Trial-stage product only
- Costs tied to study operations
- Value depends on approval path
Value-based pricing logic
TriSalus Life Sciences, Inc. likely uses value-based pricing because its liver and pancreatic cancer technologies serve a high-acuity, low-survival market, where pancreatic cancer 5-year survival is about 13% and liver cancer about 22%. That lets pricing track clinical benefit, but adoption still depends on hospital budgets, procedure use, and payer review, which is typical for specialty oncology tools.
- Prices should reflect unmet need and clinical value.
- Payer scrutiny can slow uptake.
- Adoption barriers matter as much as efficacy.
- High-acuity oncology often supports premium pricing.
TriSalus Pricing: No List Price, Just Negotiated Hospital Deals
TriSalus Life Sciences, Inc. does not disclose a public list price, so Price is set through hospital and payer contracts, not retail menus. In 2025, CMS raised hospital outpatient pay by 2.9%, which keeps reimbursement pressure high and makes value-based pricing key for TriNav and SD-101.
| Item | 2025/26 data |
|---|---|
| Public list price | None disclosed |
| CMS HOPD update | 2.9% |
| Price model | Negotiated B2B |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.